Processa Pharmaceuticals, Inc.

For Yuhan Corporation , the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been

Several major South Korean pharma firms have reported mixed first-quarter earnings, affected by varied factors including continued strength in overseas performance, solid sales of key prescription dru

Yuhan Corporation ’s first-in-class novel peptide drug candidate for degenerative disc disease (DDD), licensed out to US company Spine BioPharma in 2018, is now set to move into a Phase III trial in

Top South Korean pharma firms reported largely substantial increases in third quarter earnings, helped by increased sales of prescription products and vaccines as well as robust sales in China in some